We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

FAPON

Fapon is a global IVD raw materials & one-stop solutions company offering 700+ reagent raw materials for the applicat... read more Featured Products: More products

Download Mobile App





Fapon Highlights Innovative IVD Total Solutions and Localization Services

By LabMedica International staff writers
Posted on 13 Nov 2024

Fapon Biotech (Guangdong, China) is participating in MEDICA 2024 where the company is showcasing its IVD total solutions, including IVD raw materials, reagent services, and open-system instruments. More...

Additionally, the company is introducing its technology transfer and local manufacturing services to best underscore its commitment to quality and customer satisfaction.

At this year’s MEDICA, Fapon is presenting a suite of total solutions across various technology applications, including CLIA, biochemistry, NGS, PCR, LFA, and FIA for both clinical diagnostic labs and POCT scenarios. Leveraging its strong foundation in IVD technologies, Fapon integrates raw materials, reagent services, and open-system instruments into IVD total solutions. This approach ensures reliable, versatile, and seamless services for its IVD partners, particularly local IVD companies and distributors that are establishing or expanding their own IVD production lines. Ultimately, these efforts benefit local hospitals and patients. Fapon's goal is to elevate the portfolios of global IVD manufacturers through technology transfer and local manufacturing.

Fapon's chemiluminescence immunoassay product line being highlighted at the show exemplifies its expertise in IVD total solutions, including the Shine i-series open-system CLIA analyzers for low- to ultra-high-throughput testing, alongside over 70 reagent services for assay such as vitamin D, NT-proBNP, hs-cTnI, PCT and AD. In addition, Fapon is presenting its molecular POCT total solutions and immunofluorescence POCT total solutions, which feature fully automated molecular diagnostic analyzers, immunofluorescence POCT quantitative analyzers, and reagent services, collectively reflecting the company’s commitment to advancing diagnostic technologies for the unique needs of the IVD industry.

Fapon is committed to delivering high-performance IVD core raw materials that meet European market demands. The company’s offerings of animal-origin-free IVD raw materials address stringent market requirements and ethical considerations. Recently, Fapon launched an innovative sandwich immunoassay format for vitamin D using its high-quality raw materials, achieving superior performance and correlation compared to competitive assays. Furthermore, Fapon remains agile in meeting emerging diagnostic needs, providing testing raw materials for prevalent diseases such as SCD, mpox, and H5N1. With a strong focus on respiratory and infectious disease diagnostics, Fapon ensures its customers have access to the high-quality raw materials needed to support effective diagnostics and patient care. At MEDICA 2024, Fapon is showcasing its role as a trusted global partner in the IVD industry while meeting industry professionals, sharing insights, and exploring collaborations that drive innovation forward and improve healthcare outcomes.

Related Links:
Fapon Biotech


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Infections Test
STANDARD Q Adeno Respi Ag Test
New
Myocardial Infarction Test
Quidel Triage Cardio3 Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.